Patents by Inventor Mirjam ZEISEL

Mirjam ZEISEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma
    Patent number: 10927170
    Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: February 23, 2021
    Assignees: Universite de Strasbourg, Institut Hospitalier Universitaire de Strasbourg, Institut National de la Sante et de la Recherche Medicale
    Inventors: Thomas Baumert, Eric Robinet, Mirjam Zeisel
  • Anti-claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma
    Patent number: 10815298
    Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: October 27, 2020
    Assignees: Institut Hospitalier Universitaire de Strasbourg, Institut National de la Sante et de la Recherche Medicale, Universite de Strasbourg
    Inventors: Thomas Baumert, Eric Robinet, Mirjam Zeisel
  • ANTI-CLAUDIN 1 MONOCLONAL ANTIBODIES FOR THE PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA
    Publication number: 20180258169
    Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 13, 2018
    Inventors: Thomas BAUMERT, Eric ROBINET, Mirjam ZEISEL
  • ANTI-CLAUDIN 1 MONOCLONAL ANTIBODIES FOR THE PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA
    Publication number: 20180057587
    Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.
    Type: Application
    Filed: March 18, 2016
    Publication date: March 1, 2018
    Inventors: Thomas BAUMERT, Eric ROBINET, Mirjam ZEISEL